NEURIVE

NEURIVE operates across digital therapeutics, therapeutics and clinical-trial-related healthcare, with a focus on neurological and mental-health applications. Its products span two approaches: Soricle and HealAon use electrical and sound stimulation involving the auricular vagus nerve, while Soriclear combines tinnitus-focused cognitive behavioral therapy with personalized sound stimulation. This gives the company a portfolio that bridges device-based neuromodulation and software-led therapeutic support rather than concentrating on only one modality. The product descriptions address tinnitus, sleep, stress and other neurological or mental-health needs; the digital therapeutic is also described as MFDS-approved and available in clinical settings. NEURIVE's differentiation is therefore best assessed through its combination of stimulation hardware, tailored sound and behavioral therapy, alongside its disclosed patent activity.

NEURIVE's disclosed financing history suggests an early-stage development trajectory. It raised $163,275 in a seed round on May 1, 2020, received non-equity assistance on Jun 1, 2020 for which no amount is listed, and raised a further $847,314 in a seed round on Sep 26, 2021. The two disclosed round amounts total $1,010,589; the later seed financing is the clearest funding inflection point, with Korea Entrepreneurship Foundation, SL Investment and Magna Investment associated with that round. Product development has broadened from vagus-nerve stimulation devices, including Soricle and the wellness-oriented HealAon, to Soriclear, a digital therapeutic combining cognitive behavioral therapy and customized sound stimulation. The Mar 25, 2025 KIMES showcase and the product entry dated Feb 1, 2025 mark visible steps in bringing this work into clinical and public discussion. Patent activity across electrical stimulation, tinnitus diagnosis and vagus nerve stimulation further indicates continued technical development.